Avinger (NASDAQ:AVGR) and Regenicin (OTCMKTS:RGIN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.
This table compares Avinger and Regenicin’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Avinger has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Regenicin has a beta of 3.48, indicating that its share price is 248% more volatile than the S&P 500.
Institutional and Insider Ownership
5.6% of Avinger shares are held by institutional investors. 0.5% of Avinger shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Avinger and Regenicin’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Avinger||$7.91 million||1.92||-$27.56 million||($33.40)||-0.07|
Regenicin has lower revenue, but higher earnings than Avinger.
This is a summary of current recommendations and price targets for Avinger and Regenicin, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Avinger Company Profile
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat, and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company sells and markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.
Regenicin Company Profile
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. Its development products include NovaDerm, a cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was founded in 2007 and is based in Little Falls, New Jersey.
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.